Physician profile
Eugene R Viscusi
NPI 1184643405
$398,449.69
in general payments reported to CMS, 2019-2025
21 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $25K · 2021: $30K · 2022: $79K · 2023: $74K · 2024: $68K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $31K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Consulting Fee: $27K · Food and Beverage: $4,836 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,122.50 |
| Travel and Lodging | $31,294.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,880.00 |
| Consulting Fee | $26,552.50 |
| Food and Beverage | $4,836.41 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $235,083.93 | 2019-2025 | Zynrelef, Aponvie |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69,345.84 | 2019-2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $32,804.08 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $27,585.81 | 2019-2025 | Bridion |
| Kowa Pharmaceuticals America, INC. | $13,876.62 | 2022 | |
| Innocoll Pharmaceuticals Limited | $7,425.00 | 2021 | |
| Fresenius Kabi USA, LLC | $4,199.36 | 2020-2025 | Fentanyl Citrate |
| Btg International INC. | $3,298.43 | 2024-2025 | |
| Shionogi INC | $2,500.00 | 2019 | |
| Pajunk Medical Systems, Lp | $622.98 | 2023-2024 | E-Cath Plus Acc. Tsui |
| Tersera Therapeutics LLC | $357.81 | 2022 | |
| Avanos Medical | $241.83 | 2021-2022 | |
| Acacia Pharma INC | $197.88 | 2021 | |
| Edwards Lifesciences Corporation | $187.01 | 2022 | |
| Spr Therapeutics, INC | $150.00 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trevena, INC. | $119.44 | 2021-2022 | |
| Indivior INC. | $113.20 | 2022 | |
| Ge Healthcare | $106.47 | 2019 | |
| Ecs Opco 1 LLC | $99.93 | 2025 | Bioflo, Piccolo Medical, Cook Spectrum |
| Grt US Holding, INC. | $77.05 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $57.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Viscusi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.